Agren A, Rehn G, Naeser P
Acta Endocrinol Suppl (Copenh). 1980;239:33-6.
Glipizide dissolved in saline was given daily as a single subcutaneous injection of 20 microgram to mice with the obese-hyperglycaemic syndrome during the first month of the study. During the following three months meglumin-glipizide was used and the animals were killed after this period. Obese-hyperglycaemic control mice were given daily injections of saline. Lean untreated mice were also used as controls. No significant differences were seen between the body weights of the glipizide treated and the control mice. The results of the blood glucose estimations showed significantly lower values in the glipizide treated animals. There were no change of body weight and blood glucose concentration of the lean mice. The serum insulin levels were not changed. The ratio between endothelial cells and intramural pericytes were significantly lower in the glipizide-treated mice. It is suggested that the techniques used in these experiments may contribute to the study of early morphologic and metabolic changes in the retinal capillaries and the effect of drug treatment.
在研究的第一个月，将溶解于生理盐水中的格列吡嗪每天以20微克的剂量皮下注射给患有肥胖 - 高血糖综合征的小鼠。在接下来的三个月中使用葡甲胺 - 格列吡嗪，在此期间结束后处死动物。肥胖 - 高血糖对照小鼠每天注射生理盐水。瘦的未处理小鼠也用作对照。格列吡嗪治疗组和对照小鼠的体重之间未观察到显著差异。血糖估计结果显示，格列吡嗪治疗的动物血糖值显著较低。瘦小鼠的体重和血糖浓度没有变化。血清胰岛素水平未改变。格列吡嗪治疗的小鼠中内皮细胞与壁内周细胞的比例显著降低。建议这些实验中使用的技术可能有助于研究视网膜毛细血管的早期形态和代谢变化以及药物治疗的效果。
